scripod.com

Trump's Big Week: Middle East Trip, China Deal, Pharma EO, "Big, Beautiful Bill" with Ben Shapiro

Shownote

(0:00) The Besties welcome Ben Shapiro! (1:53) A Bestie apology to Phil Hellmuth, All-In Poker Tournament (7:58) Trump's majorly consequential Middle East trip: Saudi, Qatar, Iran, and his vision for a "New Middle East" (35:18) US-China deal: is the tid...

Highlights

In this episode, the hosts delve into a range of political and economic topics with guest Ben Shapiro. Discussions include Trump's Middle East trip, its economic outcomes, and implications for US foreign policy. The podcast also examines trade relations between the US and China, fiscal challenges facing the GOP, and controversies surrounding bans on cell-based meat.
00:00
Trump's Middle East trip aims to strengthen alliances and address regional conflicts.
01:58
We deeply regret any hurt caused to Phil Hellmuth by our previous statements.
25:25
Iran quickly capitulated following Trump's Middle East initiatives.
43:41
While some trade issues seem resolved, remaining tariffs still impact markets.
54:48
Unsustainable spending driven by gamesmanship in Congress.
1:21:03
If the product is good, it will be adopted.
1:32:39
Cost of drug trials has increased 10x from early 90s to 2025 due to regulations.

Chapters

The Besties welcome Ben Shapiro!
00:00
A Bestie apology to Phil Hellmuth, All-In Poker Tournament
01:53
Trump's majorly consequential Middle East trip: Saudi, Qatar, Iran, and his vision for a "New Middle East"
07:58
US-China deal: is the tide turning on tariffs?
35:18
GOP divided over "Big, Beautiful Bill" due to its impact on our debt spiral
46:33
Science Corner: Montana bans cell-based meat, joining Florida and others
1:18:48
Trump's EO on pharma prices: role of PBMs, is this too much government intervention?
1:24:31

Transcript

Jason Calacanis: All right, everybody, today on the All In Podcast, we're joined by our friend Ben Shapiro, and we have a full docket, including Trump's trip to the Middle East, the executive order on pharma benefits. We talk a little bit about cell-based ...